Clinical Study on the Treatment of Stage Ⅲ-Ⅳ Diabetic Kidney Disease with Yuxiao Prescription Based on the Real World
10.19879/j.cnki.1005-5304.202502457
- VernacularTitle:基于真实世界的愈消方治疗糖尿病肾病Ⅲ～Ⅳ期临床研究
- Author:
Hailan CUI
1
;
Yu LIU
;
Da LI
;
Hongtao LI
;
Zaixiang SHI
Author Information
1. 北京市昌平区中医医院,北京 102200
- Publication Type:Journal Article
- Keywords:
Yuxiao Prescription;
diabetic kidney disease;
cohort study;
real world study
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2025;32(8):159-164
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of Yuxiao Prescription in the treatment of patients with stage III-IV diabetic kidney disease(DKD)characterized by qi and yin deficiency and phlegm-stasis obstruction in the real world.Methods A total of 112 patients with stage Ⅲ-Ⅳ DKD with qi-yin deficiency and phlegm-stasis obstruction who visited the outpatient department of Beijing Changping Hospital of Traditional Chinese Medicine from April 2022 to June 2024 were selected as the research subjects.They were divided into the control group and the Chinese materia medica group based on whether they were treated with Yuxiao Prescription through prospective cohort research methods.Propensity score matching(PSM)was used to balance the confounding factors between the groups.The control group received standardized Western medicine treatment,while the Chinese materia medica group was treated with Yuxiao Prescription in addition to the treatment of the control group,one dosage per day,twice a day,orally.The treatment for both groups lasted for three months.The clinical efficacy of two groups was observed,and their urinary protein,renal function,blood glucose,blood lipids,body mass index(BMI)and TCM syndrome scores before and after treatment were compared.Adverse reactions of both groups were monitored.Results After PSM,a total of 84 balanced samples were obtained between the two groups,with 42 samples in each group.The total effective rate of Chinese materia medica group was 90.48%(38/42),while the control group was 73.81%(31/42),with statistical significance(P<0.05).Compared with before treatment,the urinary albumin/creatinine ratio,urinary microalbumin,and 24-hour urinary protein quantitative levels decreased in both groups after treatment(P<0.05).Chinese materia medica group showed a decrease in blood creatinine and a significant increase in estimated glomerular filtration rate after treatment(P<0.05);after treatment,the improvement of the above indicators in the Chinese materia medica group was better than that in the control group(P<0.05).Compared with before treatment,both groups showed a decrease in fasting blood glucose,2-hour postprandial blood glucose,glycated hemoglobin(HbA1c),total cholesterol and low-density lipoprotein cholesterol levels after treatment(P<0.05).The BMI of Chinese materia medica group significantly decreased after treatment(P<0.05);after treatment,the HbA1c level and BMI in the Chinese materia medica group were lower than those in the control group(P<0.05).Compared with before treatment,the TCM syndrome scores in both groups decreased after treatment(P<0.05);after treatment,the TCM syndrome score in the Chinese materia medica group was lower than that in the control group(P<0.05).The adverse reaction rate of the Chinese materia medica group was 4.76%(2/42),while that of the control group was 7.14%(3/42),without statistical significance between the two groups(P>0.05).Conclusion The combination of Yuxiao Prescription and conventional therapy can effectively reduce proteinuria,improve renal function,and help improve glucose and lipid metabolism in patients with stage Ⅲ-Ⅳ DKD characterized by qi and yin deficiency and phlegm-stasis obstruction,thereby delaying the progression of the disease.
